• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down1.29% Nasdaq Down3.25%

    More On NVS



    News & Info


    Analyst Coverage



    Novartis AG (NVS)

    74.33 Down 0.73(0.97%) Feb 5, 4:02PM EST
    ProfileGet Profile for:
    Novartis AG
    Lichtstrasse 35
    Basel, 4056
    Switzerland - Map
    Phone: 41 61 324 11 11
    Fax: 41 61 324 80 01
    Website: http://www.novartis.com

    Index Membership:N/A
    Industry:Drug Manufacturers - Major
    Full Time Employees:118,700

    Business Summary 

    Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The company has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and with Caribou Biosciences for the development of drug discovery tools. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Novartis AG

    Key Executives 
    Mr. Joseph Jimenez Jr., MBA, 56
    Chief Exec. Officer
    Mr. Harry Kirsch , 50
    Chief Financial Officer
    Dr. Felix R. Ehrat Ph.D., 59
    Gen. Counsel and Gen. Counsel of Novartis International Ag
    Mr. Steven Baert , 41
    Head of HR
    Mr. David R. Epstein B.Sc., M.B.A., 54
    Division Head of Novartis Pharmaceuticals
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.